ATHEROGENICS INC Form 8-K April 26, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 26, 2007

ATHEROGENICS, INC. (Exact Name of Registrant as Specified in its Charter)

Georgia	0-31261	58-2108232
(State or other	(Commission	(I.R.S. Employer
jurisdiction of incorporation)	File Number)	Identification
of meorporation)	The Number)	Number)

8995 Westside Parkway Alpharetta, GA 30004

(Address of principal executive offices)

Registrant's telephone number, including area code (678) 336-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ATHEROGENICS INC - Form 8-K

Item 2.02. Results of Operations and Financial Condition.

On April 26, 2007, AtheroGenics, Inc. issued a press release to report the company's financial results for the first quarter ended March 31, 2007. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

The following exhibit is furnished as part of this current report on Form 8-K.

<u>Exhibit</u> <u>No.</u>		Description
99.1	-	Press Release dated April 26, 2007

Edgar Filing: ATHEROGENICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ATHEROGENICS, INC.

Date: April 26, 2007

By: <u>/s/MARK P. COLONNESE</u> Mark P. Colonnese Executive Vice President, Commercial Operations and Chief Financial Officer

Edgar Filing: ATHEROGENICS INC - Form 8-K

EXHIBIT INDEX

Exhibit Description

<u>No.</u>

99.1 - Press Release dated April 26, 2007